Sodium-Glucose Co-Transporter 2 Inhibitors Reduce Macular Edema in Patients with
SGLT2
aflibercept
anti-VEGF
diabetic macular edema
sodium-glucose co-transporter 2 inhibitors
Journal
Life (Basel, Switzerland)
ISSN: 2075-1729
Titre abrégé: Life (Basel)
Pays: Switzerland
ID NLM: 101580444
Informations de publication
Date de publication:
06 May 2022
06 May 2022
Historique:
received:
10
04
2022
revised:
01
05
2022
accepted:
03
05
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
29
5
2022
Statut:
epublish
Résumé
To determine the efficacy of systemic sodium-glucose co-transporter 2 inhibitors (SGLT2i) on diabetic macular edema (DME). The medical records of patients with DME with a central retinal thickness (CRT) ≥320 µm in men and 305 µm in women, more than 6 months after the initiation of diabetes mellitus treatment, were reviewed. The CRT and best-corrected visual acuity (BCVA) were evaluated before and after the initiation of systemic SGLT2i and non-SGLT2i treatments. There were 24 eyes of 19 patients with DME that were treatment naïve or had not received treatments for the DME within four months before the initiation of SGLT2i. In these patients, the BCVA had a 0.31 ± 0.39 logarithm of the minimum angle of resolution (logMAR) units at the baseline, and it did not improve significantly at 0.26 ± 0.29 logMAR units after the initiation of SGLT2i ( These findings indicate that systemic SGLT2i can reduce DMEs, and they suggest that SGLT2i may be an additional treatment option to anti-VEGF treatments for eyes with DMEs.
Identifiants
pubmed: 35629361
pii: life12050692
doi: 10.3390/life12050692
pmc: PMC9146993
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Grant-in-Aid from the Ministry of Education, Science, Sports, and Culture of Japanese Government
ID : 16K11318
Références
Diabetes Metab Res Rev. 2019 Mar;35(3):e3113
pubmed: 30548967
Ophthalmology. 2010 Jun;117(6):1087-1093.e3
pubmed: 20299105
Diabetes Ther. 2020 Aug;11(8):1891-1905
pubmed: 32542431
Br J Ophthalmol. 2008 Dec;92(12):1581-90
pubmed: 18952646
Jpn J Ophthalmol. 2020 Mar;64(2):196-202
pubmed: 31900869
Invest Ophthalmol Vis Sci. 2012 Dec 13;53(13):8154-61
pubmed: 23132803
J Diabetes Res. 2020 Oct 14;2020:9036847
pubmed: 33123599
JAMA Ophthalmol. 2018 Mar 1;136(3):257-269
pubmed: 29392288
Am J Ophthalmol. 1999 Jun;127(6):688-93
pubmed: 10372879
BMJ Open Ophthalmol. 2018 Jul 23;3(1):e000130
pubmed: 30123844
Circ Res. 2001 Jun 8;88(11):1183-8
pubmed: 11397785
J Diabetes Investig. 2019 Mar;10(2):475-483
pubmed: 30204303
Diabetes Care. 2012 Mar;35(3):556-64
pubmed: 22301125
Case Rep Ophthalmol Med. 2020 Nov 12;2020:8867079
pubmed: 33274092
Biomed Res Int. 2017;2017:1747108
pubmed: 28758110
N Engl J Med. 2008 Oct 9;359(15):1577-89
pubmed: 18784090
N Engl J Med. 2016 Jul 28;375(4):323-34
pubmed: 27299675
Biomed Res Int. 2017;2017:7879691
pubmed: 29349082
N Engl J Med. 2020 Oct 8;383(15):1413-1424
pubmed: 32865377
Am J Case Rep. 2018 Apr 19;19:462-466
pubmed: 29670074
Glycobiology. 2017 Aug 1;27(8):691-695
pubmed: 28535208
Ophthalmology. 2015 Jul;122(7):1402-15
pubmed: 25983216
Ophthalmology. 2016 Jun;123(6):1351-9
pubmed: 26935357
Jpn J Ophthalmol. 2018 Jan;62(1):1-23
pubmed: 29210010
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
Ophthalmology. 2015 Oct;122(10):2044-52
pubmed: 26198808
Diabetes Care. 2022 Jan 1;45(Suppl 1):S125-S143
pubmed: 34964831
Diabetes Care. 2020 Feb;43(2):487-493
pubmed: 31857443
Drugs Today (Barc). 2015 Sep;51(9):519-35
pubmed: 26488032
Biomed Res Int. 2020 Nov 20;2020:4529850
pubmed: 33274211
Cardiovasc Diabetol. 2021 Jul 16;20(1):145
pubmed: 34271948